
60 Degrees Pharmaceuticals (NASDAQ:SXTP) is primarily focused on the development and commercialization of pharmaceutical products designed for the prevention and treatment of tropical diseases, including malaria and dengue. Their operations span from research and development to navigating regulatory approvals and forging key partnerships for distribution and sales. One of the prominent projects includes the development of Tafenoquine, a novel compound designed for the prevention of relapsisng malaria. With an overarching objective to address unmet medical needs in tropical medicine, 60 Degrees Pharmaceuticals is committed to leveraging scientific advancements to improve global health outcomes.